Rafi Allos
Partner
London
Rafi Allos
Partner
London
Contact Details
Rafi specialises in life sciences patents litigation and advising clients on regulatory issues in the life sciences sector. Rafi's patent litigation experience includes both representing clients in U.K. proceedings and assisting clients with multi-jurisdictional proceedings and preparation for potential litigation. In addition, Rafi has a particular interest on the interplay between life sciences regulatory issues and patent litigation and in regulatory exclusivities.
Qualifications
Professional
Solicitor-Advocate (Higher Courts Civil Proceedings), 2018
Admitted as solicitor, England and Wales, 2013
Academic
BA (First Class Hons), Jurisprudence (Law), University of Oxford, 2009
Postgraduate Diploma in Intellectual Property Law and Practice (Distinction), University of Oxford, 2014
Related articles
Blog Post: 22 March 2023
The MHRA announced on Tuesday the biggest overhaul of clinical trial regulation in the UK in 20 years. The details of the amendments to clinical trial regulation are set out in the MHRA’s response to…
Blog Post: 02 March 2023
Experience highlights
Advising Eli Lilly on UK patent and SPC litigation to secure FTO for Taltz® with respect to anti-IL-17A/F antibody patents.
Advising a global pharmaceutical company on the defence of its blockbuster monoclonal antibody against biosimilar competition, on regulatory exclusivities and SPC issues.
Advising MSD on UK and European litigation in relation to Keytruda® against BMS/Ono’s patent covering anti-PD1 antibodies.
Qualifications
Professional
Solicitor-Advocate (Higher Courts Civil Proceedings), 2018
Admitted as solicitor, England and Wales, 2013
Academic
BA (First Class Hons), Jurisprudence (Law), University of Oxford, 2009
Postgraduate Diploma in Intellectual Property Law and Practice (Distinction), University of Oxford, 2014
Other noteworthy experience
Advising:
- Global pharmaceutical company on innovator patent disputes in multiple jurisdictions involving its blockbuster monoclonal antibody drug.
- Global pharmaceutical company on the defence of its blockbuster small molecule drug against generic competition in the UK.
- A European pharmaceutical company on its patent litigation strategy, co-ordinating six European jurisdictions.
- LEO Pharma on the defence of its patents on Dovobet® (calcipotriol/betamethasone ointment) for the treatment of psoriasis.
- Various life sciences companies on regulatory matters including on data exclusivity issues; routes for obtaining marketing authorisations; biosimilars; the regulation of clinical trials; compassionate use programmes; paediatric rewards; SPCs; parallel imports; the Specific Mechanism; borderline products; and the medical devices regulatory regime.
Recognition
Excellent.
Legal 500 UK 2020: Pharmaceuticals and biotechnology (Rising Star)
Destined to be a quite exceptional figure in this field.
Legal 500, 2022: Life Sciences and Healthcare (Rising Star)
